In conclusion, our study is currently the largest cohort to reveal the potential benefit of EGFR-TKIs use in NSCLC patients harboring a sensitizing EGFR mutation, especially the del19 subgroup, who were admitted to the ICU due to respiratory failure. This evidence concerns the gene EGFR and non-small cell lung carcinoma.